To evaluate disease free survival after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies. To evaluate the incidence and severity of acute and chronic GVHD after Campath 1H-based in vivo T-cell depletion, in patients with hematologic malignancies undergoing non-myelo-ablative stem cell transplantation. To evaluate engraftment and chimerism after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies.
Zubrod performance status 2 (See Appendix B). Life expectancy is not severely limited by concomitant illness. Adequate cardiac and pulmonary function. Patients with decreased LVEF or PFTS will be evaluated by cardiology or pulmonary prior to enrollment on this protocol. Serum creatinine <1.5 mg/dL or Creatinine Clearance >50 ml/min . Serum bilirubin 2.0 mg/dl, SGPT <3 x upper limit of normal No evidence of chronic active hepatitis or cirrhosis. HIV-negative Patient is not pregnant Patient or guardian able to sign informed consent.
